Effect of Mylanta on naproxen bioavailability

Area of Science:

• Pharmacology
• Drug Interactions

Background:

• Naproxen is a common nonsteroidal anti-inflammatory drug (NSAID).
• Mylanta is an antacid frequently used for indigestion.

Purpose of the Study:

• To evaluate the effect of Mylanta on naproxen bioavailability and pharmacokinetics.
• To compare naproxen drug levels when administered with and without Mylanta.

Main Methods:

• 11 healthy volunteers received single and multiple oral doses of naproxen (250 mg) with and without Mylanta.
• Serum naproxen concentrations were measured over time.
• Pharmacokinetic parameters including AUC, Tmax, Cmax, and half-life were analyzed.
• Naproxen pharmacokinetics were also modeled using linear and non-linear protein-binding models.

Main Results:

• Coadministration of Mylanta did not significantly affect naproxen's area under the curve, time to peak concentration, peak concentration, or plasma half-life in single-dose studies.
• No significant difference was observed in steady-state trough naproxen concentrations.
• A non-linear protein-binding pharmacokinetic model accurately predicted steady-state concentrations, unlike a linear model.

Conclusions:

• Mylanta does not appear to significantly impact the bioavailability or pharmacokinetics of naproxen.
• Pharmacokinetic modeling highlights the importance of considering protein binding for accurate drug concentration predictions.